You are here: Industry Insights > RedHill Biopharma

News List

RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides Update on Enrollment in b3cnewswire
July 13, 2017
RedHill Biopharma Ltd. announced that the second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn’s disease (the MAP US study) is expected to convene in late July 2017 and will assess the safety and effi
RedHill Biopharma announces successful Phase III pharmaasia
July 04, 2017
RedHill Biopharma announces successful Phase III top-line results with BEKINDA for Acute Gastroenteritis.
RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S b3cnewswire
June 16, 2017
RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S
RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. py b3cnewswire
June 16, 2017
RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® b3cnewswire
April 19, 2017
RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once granted
RedHill Biopharma announces enrollment of last patient in BEKINDA phase III study for acute gastroen pharmaasia
March 06, 2017
Enrollment of the last patient in the Phase III study with BEKINDA 24 mg for the treatment of acute gastroenteritis and gastritis
RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroe b3cnewswire
February 14, 2017
RedHill Biopharma Ltd. announced enrollment of the last patient in the Phase III study with BEKINDA® 24 mg for the treatment of acute gastroenteritis and gastritis (the GUARD study).
RedHill Biopharma announces QIDP Fast-Track Designation granted by FDA to RHB-104 for Nontuberculous pharmaasia
February 06, 2017
RedHill Biopharma Ltd has announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) infections.

Previous page 1 2 3 Next page